Researchers at Cardiff University, in collaboration with the University of Dundee, have identified a drug molecule within a medicine used to treat tapeworm infections which could lead to new treatments for patients with Parkinson's disease.
Parkinson's disease is a long-term degenerative disorder of the central nervous system that, according to the charity, Parkinson's UK, affects one person in every 500. That means an estimated 127,000 people are currently living with Parkinson's disease in the UK alone.
Over the last decade or so, researchers striving to find a cure for this debilitating disease have focused their attention on a protein found in the human body known as PINK1. It's understood that the malfunction of this protein is one of the leading causes of Parkinson's disease.
Several studies have suggested that discovering a drug which is capable of enhancing the function of PINK1 could be a significant step in halting neurodegeneration and therefore slow down or even treat Parkinson's disease.
With this knowledge in mind, researchers at Cardiff and Dundee Universities have discovered that a drug traditionally used to treat tapeworm infections, named Niclosamide, is also an effective activator of the PINK1 protein.
Furthermore, the research, funded by The Welcome Trust, revealed that Niclosamide and some of its derivatives could enhance PINK1 performance within cells and neurons. This has given the researchers reason to believe that this drug could provide new hope for patients living with Parkinson's disease.
Dr Youcef Mehellou, from Cardiff University's School of Pharmacy and Pharmaceutical Sciences, who co-lead the study, said: 'This work represents the first report of a clinically used drug to activate PINK1 and may hold promise in treating Parkinson's disease. We will now take our findings to the next level by evaluating the ability of Niclosamide to treat Parkinson's disease in disease models. This is an exciting stage of our research and we are positive about the long term impact it could have on patients' lives."
The research 'The Anthelmintic Drug Niclosamide and its Analogues Activate the Parkinson's Disease Associated Protein Kinase PINK1' is published in iChemBioChem.
Notes for editors
1. For further information contact:
Communications & Marketing
Tel: 02920 875596
2. Cardiff University is recognised in independent government assessments as one of Britain's leading teaching and research universities and is a member of the Russell Group of the UK's most research intensive universities. The 2014 Research Excellence Framework ranked the University 5th in the UK for research excellence. Among its academic staff are two Nobel Laureates, including the winner of the 2007 Nobel Prize for Medicine, Professor Sir Martin Evans. Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The University's breadth of expertise encompasses: the College of Arts, Humanities and Social Sciences; the College of Biomedical and Life Sciences; and the College of Physical Sciences and Engineering, along with a longstanding commitment to lifelong learning. Cardiff's flagship Research Institutes are offering radical new approaches to pressing global problems. http://www.cardiff.ac.uk